09:54 AM EST - Oncolytics Biotech Inc : Announces updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma cohort. Presents updated clinical data at SITC Annual meeting showing a 69% objective response rate and confirmed complete response in GOBLET study's pancreatic cancer cohort. This data to be discussed during a key opinion leader webinar on November 14th at 10 a.m. ET. Oncolytics Biotech Inc
shares T.ONC are trading up $0.19 at $2.57.
